TRAPPC12

Across TCGA pan-cancer cohorts, TRAPPC12 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TRAPPC12 data layer compared with 23 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher TRAPPC12 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated TRAPPC12 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LUAD show a favorable association.

CCRCC, LUAD, and GBM are the cancer types where TRAPPC12 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	All	0.865	0.623	.005	17	view →
LUAD	DFS	Quartile	III,IV	1.000	0.319	.017	9	view →
GBM	OS	Tertile	All	0.404	0.660	.044	3	view →
PDAC	DFS	Tertile	All	0.346	0.591	.017	3	view →
LSCC	DFS	Quartile	II,III,IV	1.000	0.353	.024	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TRAPPC12–CCRCC (DFS)

Open the CCRCC breakdown →